文献速递前列腺癌

中危前列腺癌:分层与管理

Intermediate-risk Prostate Cancer: Stratification and Management.
PubMed 文献 · Eur Urol Oncol · 2020-04-14

本文综述中危前列腺癌分层与治疗的最佳证据,检索Medline和EMBASE至2019年9月。中危患者异质性强,可选主动监测、部分腺体消融、根治性前列腺切除术及多种放疗;NCCN等系统将其分为有利/不利亚组,但亚组内变异仍大,先进影像可能改善分层。

要点

  • 中危前列腺癌高度异质,需区分有利与不利亚组以指导治疗。
  • 有利中危患者可选主动监测或近距离单药治疗。
  • 根治性前列腺切除与剂量递增放疗联合短期雄激素剥夺有长期证据。

核心结论

  • 中危前列腺癌治疗选择从主动监测到部分腺体消融、根治性前列腺切除及多种放疗,最佳分层与治疗仍有争议。

研究设计与样本

  • 综述:检索Medline和EMBASE至2019年9月,无年份或语言限制,辅以手工检索。

主要发现

  • 根治性前列腺切除和剂量递增放疗联合短期雄激素剥夺有最佳长期证据。
  • 有利中危患者中,主动监测和近距离单药治疗也是两种有效选择。
  • 经过仔细选择的患者中,部分腺体消融是合理选择。
  • NCCN指南等分类系统将中危分为有利或不利亚组,可简化推荐但亚组内仍有显著变异。
  • 先进影像可能进一步改善当前中危患者的分层系统。

临床怎么用

  • 应结合患者偏好和合并症选择治疗方案。
  • 可利用NCCN等分类系统区分有利与不利中危以简化决策。
  • 对有利中危可考虑主动监测或近距离单药治疗。

局限性

  • 最佳分层和 Optimal 治疗仍存争议。
  • 现有分类系统亚组内仍有显著变异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Intermediate-risk prostate cancer consists of a highly heterogeneous group of patients. Owing to this heterogeneity and variable prognoses, it is challenging to provide uniform treatment recommendations for men in this group. OBJECTIVE: To review the current literature regarding the best available evidence for stratification and treatment of intermediate-risk prostate cancer patients. EVIDENCE ACQUISITION: We searched Medline and EMBASE, through September 2019 without year or language restriction, supplemented with hand search. EVIDENCE SYNTHESIS: Different treatment options with good long-term oncological outcomes are available for intermediate-risk prostate cancer patients. Best available evidence with long follow-up exists for radical prostatectomy and dose-escalated radiotherapy with short-term androgen deprivation. In favorable intermediate-risk patients, active surveillance and brachy-monotherapy also represent two valid treatment options. In carefully selected men, partial gland ablation represents a reasonable option. Patient preferences and comorbidities should also be considered. CONCLUSIONS: Treatment options for intermediate-risk patients range from active surveillance to partial gland ablation, radical prostatectomy, and various radiotherapy methods. The best stratification and the optimal treatment remain controversial. Classification systems, such as the National Cancer Comprehensive Network guidelines, stratify this large cohort into subgroups with favorable or unfavorable disease, which may simplify treatment recommendations but still leave substantial variability within strata. Advanced imaging may further improve current stratification systems of intermediate-risk patients. PATIENT SUMMARY: In this review, we assessed the current literature regarding the best available evidence for stratification and treatment of intermediate-risk prostate cancer patients.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Preisser F, Cooperberg MR, Crook J, et al. Intermediate-risk Prostate Cancer: Stratification and Management. Eur Urol Oncol. 2020. PMID: 32303478. doi:10.1016/j.euo.2020.03.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。